Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Shah T, et al. PMID 39985508
Related Questions
How does the presence of a bicuspid aortic valve influence your decision between TAVR and surgical aortic valve replacement in a patient with symptomatic aortic stenosis?
What are your top takeaways from ACC 2024?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
What is the optimal anti-platelet/anticoagulant strategy and duration following a left atrial appendage occlusion with a watchmen device and is a CTA good enough to assess if the device is well seated and without any peri device leaks?
How do you determine the feasibility of doing a valve-in-valve for patients requiring AVR with index surgical aortic valve replacement?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
What are your top 5 reasons to choose between a TAVI valve Edwards SAPIEN 3 (Edwards Lifesciences) vs an Evolut FX (Medtronic) and what favors one over the other?
What clinical or echocardiographic parameters do you use to determine the optimal timing for an aortic valve intervention in patients with asymptomatic severe aortic stenosis?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
How long should patients with atrial fibrillation who are already on systemic anticoagulation and are status post TAVR and PCI 6 months ago remain on Plavix?
